nejm semaglutide cardiovascular In patients with type 2 diabetes and atherosclerotic disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT GLP-1 receptor agonists can reduce

This medication works by mimicking the naturally occurring GLP-1 hormone, which enhances insulin secretion in response to meals, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways

Stop only if nausea prevents you from staying hydrated or eating for more than 24 hours, and contact your doctor immediately in that case

These results suggest there is no excess cardiovascular risk with tirzepatide and are consistent with the improvements of numerous surrogate markers of cardiovascular health, including weight reduction, glycemic control with less hypoglycemia, blood pressure reduction, and improvements in the lipid profile

If youre on GLP-1 for diabetes, breaks risk glucose excursions

Anxiety, much like its consequences, is one of the most rapidly spreading things in the world